Metabolic factors associated with benign prostatic hyperplasia

J. Kellogg Parsons, H. Ballentine Carter, Alan W. Partin, B. Gwen Windham, E. Metter, Luigi Ferrucci, Patricia Landis, Elizabeth A. Platz

Research output: Contribution to journalArticle

212 Citations (Scopus)

Abstract

Context: Benign prostatic hyperplasia poses a significant public health problem, but its etiology remains unclear. Obesity and associated abnormalities in glucose homeostasis may play a role in benign prostatic hyperplasia development by influencing prostate growth. Objective: The objective of this study was to determine whether obesity, fasting plasma glucose concentration, and diabetes are associated with radiologically determined prostate enlargement, an objective measure of benign prostatic hyperplasia. Design: This study was a cross-sectional analysis with robust variance estimates to account for multiple measures over time in the same individuals. Setting: This prospective cohort study was composed of community volunteers. Patients: Patients studied were 422 adult men enrolled in The Baltimore Longitudinal Study of Aging. Main Outcome Measurements: Total prostate volume as determined by pelvic magnetic resonance imaging was measured. Results: Among 422 participants, 91 (21.6%) had prostate enlargement (defined as total prostate volume ≥ 40 cc) at first visit. Compared with men of normal weight [body mass index (BMI) < 25 kg/m 2], the age-adjusted odds ratio (OR) for prostate enlargement for overweight men (BMI, 25-29.9 kg/m2) was 1.41 (95% CI, 0.84-2.37), for obese men (BMI, 30-34 kg/m2) was 1.27 (95% CI, 0.68-2.39), and for severely obese men (BMI ≥ 35 kg/m2) was 3.52 (95% CI, 1.45-8.56) (P = 0.01). Men with elevated fasting glucose (>110 mg/dl) were more likely to have an enlarged prostate than men with normal fasting glucose (≤110 mg/dl) (OR, 2.98; 95% CI, 1.70-5.23), as were men with a diagnosis of diabetes (OR, 2.25; 95% CI, 1.23-4.11). Conclusions: Obesity, elevated fasting plasma glucose, and diabetes are risk factors for benign prostatic hyperplasia.

Original languageEnglish (US)
Pages (from-to)2562-2568
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume91
Issue number7
DOIs
StatePublished - Jul 14 2006

Fingerprint

Prostatic Hyperplasia
Medical problems
Prostate
Glucose
Fasting
Obesity
Plasmas
Public health
Magnetic resonance
Baltimore
Aging of materials
Imaging techniques
Longitudinal Studies
Volunteers
Body Mass Index
Homeostasis
Cohort Studies
Public Health
Cross-Sectional Studies
Magnetic Resonance Imaging

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Parsons, J. K., Carter, H. B., Partin, A. W., Windham, B. G., Metter, E., Ferrucci, L., ... Platz, E. A. (2006). Metabolic factors associated with benign prostatic hyperplasia. Journal of Clinical Endocrinology and Metabolism, 91(7), 2562-2568. https://doi.org/10.1210/jc.2005-2799

Metabolic factors associated with benign prostatic hyperplasia. / Parsons, J. Kellogg; Carter, H. Ballentine; Partin, Alan W.; Windham, B. Gwen; Metter, E.; Ferrucci, Luigi; Landis, Patricia; Platz, Elizabeth A.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 91, No. 7, 14.07.2006, p. 2562-2568.

Research output: Contribution to journalArticle

Parsons, JK, Carter, HB, Partin, AW, Windham, BG, Metter, E, Ferrucci, L, Landis, P & Platz, EA 2006, 'Metabolic factors associated with benign prostatic hyperplasia', Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 7, pp. 2562-2568. https://doi.org/10.1210/jc.2005-2799
Parsons, J. Kellogg ; Carter, H. Ballentine ; Partin, Alan W. ; Windham, B. Gwen ; Metter, E. ; Ferrucci, Luigi ; Landis, Patricia ; Platz, Elizabeth A. / Metabolic factors associated with benign prostatic hyperplasia. In: Journal of Clinical Endocrinology and Metabolism. 2006 ; Vol. 91, No. 7. pp. 2562-2568.
@article{ac74ef6a45064ab6b7f2d54127ec9f22,
title = "Metabolic factors associated with benign prostatic hyperplasia",
abstract = "Context: Benign prostatic hyperplasia poses a significant public health problem, but its etiology remains unclear. Obesity and associated abnormalities in glucose homeostasis may play a role in benign prostatic hyperplasia development by influencing prostate growth. Objective: The objective of this study was to determine whether obesity, fasting plasma glucose concentration, and diabetes are associated with radiologically determined prostate enlargement, an objective measure of benign prostatic hyperplasia. Design: This study was a cross-sectional analysis with robust variance estimates to account for multiple measures over time in the same individuals. Setting: This prospective cohort study was composed of community volunteers. Patients: Patients studied were 422 adult men enrolled in The Baltimore Longitudinal Study of Aging. Main Outcome Measurements: Total prostate volume as determined by pelvic magnetic resonance imaging was measured. Results: Among 422 participants, 91 (21.6{\%}) had prostate enlargement (defined as total prostate volume ≥ 40 cc) at first visit. Compared with men of normal weight [body mass index (BMI) < 25 kg/m 2], the age-adjusted odds ratio (OR) for prostate enlargement for overweight men (BMI, 25-29.9 kg/m2) was 1.41 (95{\%} CI, 0.84-2.37), for obese men (BMI, 30-34 kg/m2) was 1.27 (95{\%} CI, 0.68-2.39), and for severely obese men (BMI ≥ 35 kg/m2) was 3.52 (95{\%} CI, 1.45-8.56) (P = 0.01). Men with elevated fasting glucose (>110 mg/dl) were more likely to have an enlarged prostate than men with normal fasting glucose (≤110 mg/dl) (OR, 2.98; 95{\%} CI, 1.70-5.23), as were men with a diagnosis of diabetes (OR, 2.25; 95{\%} CI, 1.23-4.11). Conclusions: Obesity, elevated fasting plasma glucose, and diabetes are risk factors for benign prostatic hyperplasia.",
author = "Parsons, {J. Kellogg} and Carter, {H. Ballentine} and Partin, {Alan W.} and Windham, {B. Gwen} and E. Metter and Luigi Ferrucci and Patricia Landis and Platz, {Elizabeth A.}",
year = "2006",
month = "7",
day = "14",
doi = "10.1210/jc.2005-2799",
language = "English (US)",
volume = "91",
pages = "2562--2568",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "7",

}

TY - JOUR

T1 - Metabolic factors associated with benign prostatic hyperplasia

AU - Parsons, J. Kellogg

AU - Carter, H. Ballentine

AU - Partin, Alan W.

AU - Windham, B. Gwen

AU - Metter, E.

AU - Ferrucci, Luigi

AU - Landis, Patricia

AU - Platz, Elizabeth A.

PY - 2006/7/14

Y1 - 2006/7/14

N2 - Context: Benign prostatic hyperplasia poses a significant public health problem, but its etiology remains unclear. Obesity and associated abnormalities in glucose homeostasis may play a role in benign prostatic hyperplasia development by influencing prostate growth. Objective: The objective of this study was to determine whether obesity, fasting plasma glucose concentration, and diabetes are associated with radiologically determined prostate enlargement, an objective measure of benign prostatic hyperplasia. Design: This study was a cross-sectional analysis with robust variance estimates to account for multiple measures over time in the same individuals. Setting: This prospective cohort study was composed of community volunteers. Patients: Patients studied were 422 adult men enrolled in The Baltimore Longitudinal Study of Aging. Main Outcome Measurements: Total prostate volume as determined by pelvic magnetic resonance imaging was measured. Results: Among 422 participants, 91 (21.6%) had prostate enlargement (defined as total prostate volume ≥ 40 cc) at first visit. Compared with men of normal weight [body mass index (BMI) < 25 kg/m 2], the age-adjusted odds ratio (OR) for prostate enlargement for overweight men (BMI, 25-29.9 kg/m2) was 1.41 (95% CI, 0.84-2.37), for obese men (BMI, 30-34 kg/m2) was 1.27 (95% CI, 0.68-2.39), and for severely obese men (BMI ≥ 35 kg/m2) was 3.52 (95% CI, 1.45-8.56) (P = 0.01). Men with elevated fasting glucose (>110 mg/dl) were more likely to have an enlarged prostate than men with normal fasting glucose (≤110 mg/dl) (OR, 2.98; 95% CI, 1.70-5.23), as were men with a diagnosis of diabetes (OR, 2.25; 95% CI, 1.23-4.11). Conclusions: Obesity, elevated fasting plasma glucose, and diabetes are risk factors for benign prostatic hyperplasia.

AB - Context: Benign prostatic hyperplasia poses a significant public health problem, but its etiology remains unclear. Obesity and associated abnormalities in glucose homeostasis may play a role in benign prostatic hyperplasia development by influencing prostate growth. Objective: The objective of this study was to determine whether obesity, fasting plasma glucose concentration, and diabetes are associated with radiologically determined prostate enlargement, an objective measure of benign prostatic hyperplasia. Design: This study was a cross-sectional analysis with robust variance estimates to account for multiple measures over time in the same individuals. Setting: This prospective cohort study was composed of community volunteers. Patients: Patients studied were 422 adult men enrolled in The Baltimore Longitudinal Study of Aging. Main Outcome Measurements: Total prostate volume as determined by pelvic magnetic resonance imaging was measured. Results: Among 422 participants, 91 (21.6%) had prostate enlargement (defined as total prostate volume ≥ 40 cc) at first visit. Compared with men of normal weight [body mass index (BMI) < 25 kg/m 2], the age-adjusted odds ratio (OR) for prostate enlargement for overweight men (BMI, 25-29.9 kg/m2) was 1.41 (95% CI, 0.84-2.37), for obese men (BMI, 30-34 kg/m2) was 1.27 (95% CI, 0.68-2.39), and for severely obese men (BMI ≥ 35 kg/m2) was 3.52 (95% CI, 1.45-8.56) (P = 0.01). Men with elevated fasting glucose (>110 mg/dl) were more likely to have an enlarged prostate than men with normal fasting glucose (≤110 mg/dl) (OR, 2.98; 95% CI, 1.70-5.23), as were men with a diagnosis of diabetes (OR, 2.25; 95% CI, 1.23-4.11). Conclusions: Obesity, elevated fasting plasma glucose, and diabetes are risk factors for benign prostatic hyperplasia.

UR - http://www.scopus.com/inward/record.url?scp=33745780938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745780938&partnerID=8YFLogxK

U2 - 10.1210/jc.2005-2799

DO - 10.1210/jc.2005-2799

M3 - Article

C2 - 16608892

AN - SCOPUS:33745780938

VL - 91

SP - 2562

EP - 2568

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 7

ER -